Press

2023-05-19

Interim Report First Quarter 2023 January 1 – March 31 2023 Kancera AB (publ.), org.no. 556806-8851

The period in briefJanuary – MarchFinancial summary for the first quarter• Net sales amounted to SEK 0 million (SEK 0).• R&D expenses amounted to SEK 15,2 million (SEK10,6 million).• Operating profit for the first quarter amounted to SEK -17.2...

Read More
2022-07-29

Correction: Interim report first quarter 2022, 1 January – 31 March 2022 Kancera AB (publ.), org.nr. 556806-8851

Due to technical reasons this report was only published as a press release, but did not show up in the Finacial reports section on the Kancera web page. This is now corrected. First quarter in brief January – MarchFinancial...

Read More
2021-05-21

Interim report for first quarter 2021, 1 January – 31 March 2021

First quarter in brief Net sales for the period (January to March) amounted to SEK 0 million (SEK 0 million). R&D costs for the period amounted to SEK 8,2 million (SEK 9,7 million). Operating profit for the period amounted...

Read More
2020-06-10

Interim report for the first quarter 2020, 1 januari-31 March 2020 Kancera AB (publ.), org.nr. 556806-8851.

First quarter in brief 1 January – 31 March 2020 Net sales for the period (January to March) amounted to SEK 0,04 million (3,1). R&D costs for the period amounted to SEK 9,7 million (10,2). Operating profit for the...

Read More
2019-05-24

INTERIM REPORT FOR THE FIRST QUARTER 2019, 1 January – 31 March 2019

First quarter in brief 1 January – 31 March 2019 Net sales for the period (January to March) amounted to SEK 0.0 million (SEK 0.0 million) R&D costs for the period amounted to SEK 10,2 million (SEK 11,8 million)....

Read More
2018-06-07

INTERIM REPORT FOR KANCERA  AB (publ) 1st January – 31st March 2018

PERIOD 1 JAN – 31 MARCH 2018 IN BRIEF • Net sales amounted to SEK 0 million (0 million) • R & D expenses amounted to SEK 11.8 million (8.3 M) • Operating profit amounted to SEK -12.5 million (-9.7 million) •...

Read More
2016-05-03

Interim Report for Kancera AB (publ) Q1 2016, January 1 – March 31, 2016

The period January to March 2016 in brief R&D expenses for the period amounted to SEK 4.2m (SEK 4.2m). Operating income for the period amounted to SEK -5.1m (SEK 4.9m). Income after financial items for the period amounted to...

Read More
2015-05-22

Interim Report for Kancera AB (publ) Q1 2015 January 1 – March 31, 2015

In 2013 Kancera changed from the RFR2 regulations, applicable to companies in groups, to BFN ́s complementary regulation K3. The full year report and consolidated accounts fulfill the requirements of Nasdaq First North for the accounting of Kancera AB....

Read More
2014-05-23

Interim Report for Kancera AB (publ) Q1 2014

All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there are no consolidated accounts for the Kancera Group produced...

Read More
2013-05-24

Interim Report for Kancera AB (publ) Q1 2013

January 1 - March 31, 2013 All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB. Therefore there are no consolidated accounts for the Kancera Group...

Read More